![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Rilpivirine (TMC278) tolerability over the first 12 weeks of treatmentin the Phase III ECHO and THRIVE studies
|
|
|
Reported by Jules Levin
51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20 2011
Bruce Rashbaum,1 Pierre-Marie Girard,2 Anita Rachlis,3 Diana Pedral-Sampaio,4 Aimee Wilkin,5 Simon Vanveggel,6 Katia Boven7
1Capital Medical Associates, Washington, DC, USA; 2Hôpital Saint Antoine, Paris, France; 3Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; 4Federal University of Bahia, Brazil;5Wake Forest University Health Sciences, Winston-Salem, NC, USA; 6Tibotec BVBA, Beerse, Belgium; 7Tibotec Inc. Titusville, NJ, USA
![ICAAC1.gif](../images/092211/092211-3/ICAAC1.gif)
![ICAAC2.gif](../images/092211/092211-3/ICAAC2.gif)
![ICAAC3.gif](../images/092211/092211-3/ICAAC3.gif)
![ICAAC4.gif](../images/092211/092211-3/ICAAC4.gif)
![ICAAC5.gif](../images/092211/092211-3/ICAAC5.gif)
![ICAAC6.gif](../images/092211/092211-3/ICAAC6.gif)
![ICAAC7.gif](../images/092211/092211-3/ICAAC7.gif)
![ICAAC8.gif](../images/092211/092211-3/ICAAC8.gif)
![ICAAC9.gif](../images/092211/092211-3/ICAAC9.gif)
![ICAAC10.gif](../images/092211/092211-3/ICAAC10.gif)
![ICAAC11.gif](../images/092211/092211-3/ICAAC11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|